Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
22nd Century Group Announces Closing of $6 Million Registered Direct Offering
-
StemCells, Inc. Announces Closing of Over-Allotment Option
-
Notable Analyst Rating Changes 5/29: (MX) (CPRT) Upgraded; (HIMX) (ANF) (URI) Downgraded
-
Pre-Open Stock Movers 05/29: (TBIO) (HRTX) (NQ) Higher; (FRO) (SPLK) (CYBR) Lower (more...)
-
UPDATE: Chardan Capital Markets Cuts Himax Technologies (HIMX) to Sell; Samsung Moving to AMOLED Would be Huge Blow
-
Chardan Capital Markets Starts Amicus Therapeutics (FOLD) at Buy
-
22nd Century Group (XXII) Enters 6M Common Stock, 3M Warrants Registered Direct Offering
-
22nd Century Group Announces $6 Million Registered Direct Offering
-
Notable Analyst Rating Changes 5/22: (RWLK) (BAH) (DOV) Upgraded; (GD) (JGW) (CONN) Downgraded
-
Chardan Capita Starts Esperion Therapeutics (ESPR) at Sell; Post-IPO Run Leads to Unfavorable Risk-Reward
-
Chardan Capital Markets Starts Esperion Therapeutics (ESPR) at Sell
-
REGENXBIO Secures $70.5 Million in a Mezzanine Financing
-
REGENXBIO Secures $70.5 Million in a Mezzanine Financing
-
Chardan Capital Lifts PT on Immune Pharma (IMNP) to $6 Following Q1 Report; AmiKet Appears on Track
-
Camtek Ltd (CAMT) Prices 4.3M Common Offering at $2.85/Share
-
Camtek Prices Underwritten Public Offering of Ordinary Shares
-
CORRECTION - Camtek Ltd: Camtek Prices Underwritten Public Offering of Ordinary Shares
-
NeuroVive Pharmaceutical: NeuroVive Completes Share Issue Raising SEK 70 Million for the Preparation of CicloMulsion®’s Clinical Trial in the US and Commercialization in Europe
-
Chardan Capital Markets Starts U.S. Geothermal (HTM) at Neutral
-
Chardan Capital Markets Upgrades CEVA Inc. (CEVA) to Buy
-
Chardan Capital Markets Starts Check-Cap (CHEK) at Buy
-
StemCells, Inc. Announces Closing of $25 Million Public Offering
-
Notable Analyst Rating Changes 4/29: (LLY) (VOD) (UPS) Upgraded; (GLW) (ETR) (NOV) Downgraded
-
Chardan Capital Markets Starts Lion Biotechnologies (LBIO) at Buy, PT $30
-
New C Media Partnership Demonstrates YOU On Demand's (YOD) Desire to Diversify - Chardan Capital
-
MassRoots Partners with Seed-to-Sale System Flowhub; Crosses 300 Dispensaries on Network
-
Notable Analyst Rating Changes 4/24: (MAT) (TEL) (CVC) Upgraded; (BBY) (NKE) (GM) Downgraded
-
Smoofi Announces Agreement With Licensed Cultivator in Colorado
-
StemCells (STEM) Prices Common, Warrants Offering at $0.70/Unit
-
StemCells, Inc. Announces Pricing of Public Offering to Raise $25 Million
-
StemCells, Inc. Announces Pricing of Public Offering to Raise $25 Million
-
Smoofi Announces Agreement With Licensed Cultivator in Colorado
-
Chardan Capital Markets Starts uniQure BV (QURE) at Buy; Sees 2015 as 'Breakthrough' Year
-
SPYR, INC. Retains Investment Banking Firm to Assist With Strategic Mergers and Acquisitions
-
Chardan Capital Cuts PT on Himax (HIMX) to $6; High Inventories, Weak Sell-Through May Impact Q2 Results
-
Chardan Trims PT on YOU on Demand (YOD) to $5; Affirms 'Buy' Rating Following Q4 Report
-
Chardan Capital Issues Industry Note Covering Spherix
-
Chardan Capital Markets Downgrades Ohr Pharmaceutical (OHRP) to Neutral (Earlier)
-
Drone Momentum to Benefit Ambarella (AMBA), Chardan Capital Says; Buy on Pullback
-
Ecolomondo (EECO) Files $16.1M IPO
-
Chardan Capital Markets Starts Aldeyra Therapeutics (ALDX) at Buy
-
Attending Firms Announced for the Growth Capital Expo, April 12-14, 2015
-
Chardan Capital Markets Starts Regeneron Pharma (REGN) at Buy
-
Integrated Device Technology (IDTI) Highlighted Ahead of Apple Watch Event; Wireless Charging?
-
Chardan Capital Markets Starts Immune Pharmaceuticals (IMNP) at Buy; $5.50 PT
-
Chardan Capital Markets Starts Catasys (CATS) at Buy
-
Top Emerging Growth Experts, Investors and Entrepreneurs to Lead Discussion Panels at Growth Capital Expo 2015
-
Chardan Capital Keeps Globalstar (GSAT) at 'Buy'; TLPS Ruling Remains Key Item
-
Chardan Capital Resumes La Jolla Pharma (LJPC) at Buy; Sees Sales Over $1B by FY22
-
Chardan Capital Markets Assumes Medical Transcription Billing (MTBC) at Buy

